Relmada Therapeutics, Inc. (RLMD) NASDAQ

2.21

+0.07(+3.27%)

Updated at October 23 04:00PM

Currency In USD

Relmada Therapeutics, Inc.

Address

2222 Ponce de Leon Boulevard

Coral Gables, FL 33134

United States of America

Phone

786 629 1376

Sector

Healthcare

Industry

Biotechnology

Employees

17

First IPO Date

June 20, 2014

Key Executives

NameTitlePayYear Born
Dr. Sergio Traversa M.B.A., Pharm.D.Chief Executive Officer & Director1.8M1960
Mr. Paul E. Kelly M.B.A.Chief Operating Officer & Director872,7801957
Mr. Charles S. Ence CPA, M.B.A.Chief Accounting & Compliance Officer983,0391965
Mr. Maged S. Shenouda M.B.A., R.Ph.Chief Financial Officer993,7501964
Dr. Richard M. Mangano Ph.D.Consultant01950
Dr. Andrew CutlerSenior Clinical Development Advisor0N/A
Ms. Gina DiGuglielmoVice President & Head of Clinical Operations0N/A

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.